登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C6H12NO5P
化学文摘社编号:
分子量:
209.14
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
SMILES string
[P](=O)(O)(O)C\C(=C\C(N)C(=O)O)\C
InChI
1S/C6H12NO5P/c1-4(3-13(10,11)12)2-5(7)6(8)9/h2,5H,3,7H2,1H3,(H,8,9)(H2,10,11,12)/b4-2+
InChI key
BDYHNCZIGYIOGJ-DUXPYHPUSA-N
assay
≥99% (HPLC)
form
solid
potency
35 nM Ki
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
white
solubility
H2O: 100 mM
Quality Level
正在寻找类似产品? 访问 产品对比指南
General description
A highly potent competitive antagonist selective for NMDA receptors (Ki = 35 nM). Biologically viable admitted orally or systematically. Widely used in studies of epilepsy, schizophrenia, depression, stress and anxiety related mental disorders.
Biochem/physiol Actions
Primary Target
NMDA receptors
NMDA receptors
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Slight warming is required for complete solubilization.
Other Notes
Serafini, G., et al. 2013. Curr. Pharmaceut. Design19, 1898.
Szewczyk, B., et al. 2012. Expert. Op. Invest. Drugs21, 91.
Przegalinski, E., et al. 2000. Neuropharmacol.39, 1858.
Maj, J., et al. 1993. Polish J. Pharmacol.45, 455.
Fagg, E., et al. 1990. Br. J. Pharmacol.99, 791.
Schmutz, M., et al. 1990. Naunyn-Schmiedebergʹs Arch. Pharmacol.342, 61.
Szewczyk, B., et al. 2012. Expert. Op. Invest. Drugs21, 91.
Przegalinski, E., et al. 2000. Neuropharmacol.39, 1858.
Maj, J., et al. 1993. Polish J. Pharmacol.45, 455.
Fagg, E., et al. 1990. Br. J. Pharmacol.99, 791.
Schmutz, M., et al. 1990. Naunyn-Schmiedebergʹs Arch. Pharmacol.342, 61.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持